Read more

July 31, 2024
1 min read
Save

ASRS 2024: Healio’s top stories so far

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.

Check out these ASRS 2024 articles and more below.

Graphic distinguishing meeting news
Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.

Luxturna shows long-term maintenance of ambulatory vision, visual field

Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients with biallelic RPE65 mutation-associated retinal diseases, according to a study. Read more.

Macular hole closure rate better with ILM peeling vs. PPV alone

Pars plana vitrectomy with internal limiting membrane peeling for macular hole closure is better than pars plana vitrectomy without internal limiting membrane peeling, according to a presentation. Read more.

4D-150 reduces annualized anti-VEGF injection rate in wet AMD at 24 weeks

One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a population extension study. Read more.

Patients may benefit from early epiretinal membrane peel after PVR repair

Patients with epiretinal membrane after proliferative vitreoretinopathy repair may benefit from early peeling, according to a presenter. Read more.

Real-world study explores safety of pegcetacoplan in geographic atrophy

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials. Read more.